BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough
Gotistobart nearly doubled median overall survival versus standard-of-care docetaxel in BioNTech’s Phase 3 PRESERVE-003 trial for metastatic squamous non-small cell lung cancer (median not reached vs 9.95 months), with 12-month progression-free survival of 25.2% vs 0%.
Sep 15, 2026 ·
Yahoo Finance


















